PHASE II TRIAL OF FOLFOX6, BEVACIZUMAB AND CETUXIMAB IN PATIENTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the safety, feasibility of administration, response and survival rates among patients with advanced colorectal cancer treated with the combination of drugs, Folfox6, Bevacizumab and Cetuximab.